WO2019023039A3 - Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances - Google Patents

Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances Download PDF

Info

Publication number
WO2019023039A3
WO2019023039A3 PCT/US2018/042885 US2018042885W WO2019023039A3 WO 2019023039 A3 WO2019023039 A3 WO 2019023039A3 US 2018042885 W US2018042885 W US 2018042885W WO 2019023039 A3 WO2019023039 A3 WO 2019023039A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceuticals
compositions
supplements
enhancing bioavailability
ingested substances
Prior art date
Application number
PCT/US2018/042885
Other languages
French (fr)
Other versions
WO2019023039A2 (en
Inventor
Andrew R. Lefkowitz
Sean Farmer
Ken Alibek
Alibek MOLDAKOZHAYEV
Original Assignee
Locus Ip Company, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202211737163.9A priority Critical patent/CN116617384A/en
Priority to EP18837671.9A priority patent/EP3658124A4/en
Priority to CN201880063445.0A priority patent/CN111148511A/en
Priority to KR1020207004851A priority patent/KR20200024940A/en
Priority to US16/632,626 priority patent/US11590231B2/en
Priority to AU2018307361A priority patent/AU2018307361A1/en
Priority to JP2020503843A priority patent/JP2020528898A/en
Priority to CA3070711A priority patent/CA3070711C/en
Application filed by Locus Ip Company, Llc filed Critical Locus Ip Company, Llc
Priority to BR112020001759-0A priority patent/BR112020001759A2/en
Priority to SG11202000670VA priority patent/SG11202000670VA/en
Publication of WO2019023039A2 publication Critical patent/WO2019023039A2/en
Publication of WO2019023039A3 publication Critical patent/WO2019023039A3/en
Priority to ZA2020/00327A priority patent/ZA202000327B/en
Priority to IL272168A priority patent/IL272168A/en
Priority to US18/175,020 priority patent/US20230201352A1/en
Priority to JP2023127634A priority patent/JP2024001005A/en
Priority to US18/460,763 priority patent/US20230405127A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to compositions and methods for enhancing bioavailability of health-promoting substances, such as pharmaceuticals and nutritional supplements. The subject invention utilizes an adjuvant composition comprising one or more microbial-produced biosurfactants and/or isoforms thereof, to enhance bioavailability of health-promoting substances and to reduce the effective dosage that is required.
PCT/US2018/042885 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances WO2019023039A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR112020001759-0A BR112020001759A2 (en) 2017-07-27 2018-07-19 compositions for enhancing the bioavailability of pharmaceutical products, supplements and ingested substances
EP18837671.9A EP3658124A4 (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
SG11202000670VA SG11202000670VA (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
US16/632,626 US11590231B2 (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
AU2018307361A AU2018307361A1 (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
JP2020503843A JP2020528898A (en) 2017-07-27 2018-07-19 Compositions that enhance the bioavailability of pharmaceuticals, supplements and ingested substances
CA3070711A CA3070711C (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
CN202211737163.9A CN116617384A (en) 2017-07-27 2018-07-19 Compositions for improving bioavailability of drugs, supplements and ingested substances
CN201880063445.0A CN111148511A (en) 2017-07-27 2018-07-19 Composition for improving bioavailability of drugs, supplements and ingested substances
KR1020207004851A KR20200024940A (en) 2017-07-27 2018-07-19 Compositions for Improving Bioavailability of Drugs, Supplements and Ingested Substances
ZA2020/00327A ZA202000327B (en) 2017-07-27 2020-01-17 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
IL272168A IL272168A (en) 2017-07-27 2020-01-21 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
US18/175,020 US20230201352A1 (en) 2017-07-27 2023-02-27 Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances
JP2023127634A JP2024001005A (en) 2017-07-27 2023-08-04 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
US18/460,763 US20230405127A1 (en) 2017-07-27 2023-09-05 Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762537502P 2017-07-27 2017-07-27
US62/537,502 2017-07-27
US201862647974P 2018-03-26 2018-03-26
US62/647,974 2018-03-26
US201862690365P 2018-06-27 2018-06-27
US62/690,365 2018-06-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/632,626 A-371-Of-International US11590231B2 (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
US18/175,020 Continuation US20230201352A1 (en) 2017-07-27 2023-02-27 Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances

Publications (2)

Publication Number Publication Date
WO2019023039A2 WO2019023039A2 (en) 2019-01-31
WO2019023039A3 true WO2019023039A3 (en) 2019-03-28

Family

ID=65041332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/042885 WO2019023039A2 (en) 2017-07-27 2018-07-19 Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances

Country Status (14)

Country Link
US (3) US11590231B2 (en)
EP (1) EP3658124A4 (en)
JP (2) JP2020528898A (en)
KR (1) KR20200024940A (en)
CN (2) CN116617384A (en)
AU (1) AU2018307361A1 (en)
BR (1) BR112020001759A2 (en)
CA (1) CA3070711C (en)
IL (1) IL272168A (en)
MX (1) MX2022014291A (en)
SG (1) SG11202000670VA (en)
TW (1) TW201909919A (en)
WO (1) WO2019023039A2 (en)
ZA (1) ZA202000327B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116617384A (en) 2017-07-27 2023-08-22 轨迹Ip有限责任公司 Compositions for improving bioavailability of drugs, supplements and ingested substances
EP3731804A4 (en) 2017-12-28 2022-01-05 Locus IP Company, LLC Oral health composition comprising purified biosurfactants and/or their derivatives
EP3801463A4 (en) 2018-05-25 2022-05-04 Locus IP Company, LLC Therapeutic compositions for enhanced healing of wounds and scars
EP4009949A4 (en) 2019-08-10 2023-08-16 Locus IP Company, LLC Olfactory delivery of therapeutic compounds to the central nervous system
US20220313659A1 (en) * 2019-08-10 2022-10-06 Locus Ip Company, Llc Methods for Increasing the Bioavailability of OTC and Pharmaceutical Drugs
WO2021030702A1 (en) 2019-08-14 2021-02-18 Locus Ip Company, Llc Drinkable supplement composition for improved health and hydration
CN112369542A (en) * 2019-10-28 2021-02-19 广州富诺营养科技有限公司 Mushroom powder solid beverage and preparation method thereof
IL296498A (en) * 2020-03-20 2022-11-01 Locus Ip Co Llc Materials and methods for the efficient dispersion of nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902512A (en) * 1987-01-22 1990-02-20 Director-General Of Agency Of Industrial Science And Technology And Shin-Etsu Chemical Co., Ltd. Rhamnolipid liposomes
US20050031549A1 (en) * 2003-06-09 2005-02-10 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
CN103007287A (en) * 2012-09-29 2013-04-03 湖州紫金生物科技有限公司 Application of rhamnolipid as oral medicine absorbent accelerant
US20140187507A1 (en) * 2012-12-14 2014-07-03 Rutgers, The State University Of New Jersey Treatment of parkinsons disease with glycolipids
US20140255420A1 (en) * 2008-01-18 2014-09-11 The Brigham And Women's Hospital, Inc. Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759057B1 (en) * 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
EP0540074A1 (en) 1991-10-09 1993-05-05 ENIRICERCHE S.p.A. Cloning and sequencing of that chromosomal DNA region of bacillus subtilis comprising the SRFA operon which encodes the multienzymatic complex surfactin synthetase
FR2720941B1 (en) * 1994-06-13 1996-08-23 Inst Francais Du Petrole Use of sophorolipids and cosmetic and dermatological compositions.
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
FR2735979B1 (en) 1995-06-28 1997-08-14 Inst Francais Du Petrole USE AS THERAPEUTICALLY ACTIVE SUBSTANCES OR COSMETIC PRODUCTS OF SOPHOROLIPIDS, PARTICULARLY FOR THE TREATMENT OF THE SKIN
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
AU3547499A (en) 1998-03-31 1999-10-18 Abbott Laboratories Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof
FR2779057B1 (en) * 1998-05-29 2001-06-15 Inst Francais Du Petrole USE OF SOPHOROLIPIDS COMPRISING DIACETYLATED LACTONS AS A STIMULATOR OF THE METABOLISM OF FIBROBLASTS OF THE SKIN
US20020123077A1 (en) 2000-09-29 2002-09-05 O'toole George A. Novel compounds capable of modulating biofilms
JP4370591B2 (en) 2001-07-31 2009-11-25 独立行政法人産業技術総合研究所 Liposomes and carriers for introducing substances into cells comprising the same
WO2003070181A2 (en) 2002-02-19 2003-08-28 Eden Research Plc Compositions and methods for preservation of food
JP4452799B2 (en) 2004-07-14 2010-04-21 独立行政法人産業技術総合研究所 Method for producing liposome using coacervate
JP4878748B2 (en) 2004-11-09 2012-02-15 学校法人近畿大学 Acetylcholinesterase inhibitor
US8685942B2 (en) * 2010-04-05 2014-04-01 Richard A. Gross Sophorolipid analog compositions
KR100785656B1 (en) 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 Sodium glycocholate or derivatives thereof used as anti-inflammatory agents
US20100280111A1 (en) * 2007-12-28 2010-11-04 Showa Denko K.K. Skin external preparations and cosmetics
EP2245136A4 (en) 2008-01-18 2011-06-29 Bio Proc Australia Pty Ltd Process for preparing nutritional, therapeutic or organoleptic products from crude glycerol
EP2563916B1 (en) 2010-04-27 2015-07-08 Lysando AG Method of reducing biofilms
US8361779B2 (en) 2010-11-24 2013-01-29 Sachem, Inc. Buffer compounds
US20120142621A1 (en) 2010-12-03 2012-06-07 Biomedica Management Corporation Purified Ethyl Ester Sophorolipid for the Treatment of Sepsis
CN103732064A (en) 2011-05-24 2014-04-16 拜尔作物科学有限合伙公司 Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use
EP2794865B1 (en) * 2011-12-20 2018-04-25 Universiteit Gent A lactonase derived from candida bombicola and uses thereof
CN104321422A (en) 2012-01-27 2015-01-28 Gfs澳大利亚股份有限公司 Method of producing biosurfactants
WO2013129667A1 (en) 2012-03-02 2013-09-06 サラヤ株式会社 High-purity acid-form sophorolipid (sl) containing composition and process for preparing same
JP2014034552A (en) 2012-08-09 2014-02-24 Kao Corp Biofilm formation inhibitor
CN102988981B (en) 2012-12-13 2015-03-04 中国水产科学研究院黄海水产研究所 Adjuvant for improving immunization effect of Edwardsiella vaccine and use method of adjuvant
CN104869978B8 (en) * 2012-12-17 2017-09-12 荷兰联合利华有限公司 Personal care composition
WO2014120247A1 (en) 2013-02-02 2014-08-07 Polytechnic Institute Of New York University Modified sophorolipids combinations as antimicrobial agents
EP2792302A1 (en) 2013-04-17 2014-10-22 Institut Pasteur Olfactory means useful in the diagnosis and treatment of mood depression
PT106959B (en) 2013-05-17 2020-04-20 Inst Superior Tecnico PROCESSES FOR THE PRODUCTION OF MICROBIAL GLYCOLIPIDES OF THE MANOSILERITRITOLIPID TYPE, FROM LEMOCELLULOSIC MATERIALS AND THEIR APPLICATIONS
US9585903B2 (en) 2013-09-30 2017-03-07 Council Of Scientific & Industrial Research Pharmaceutical composition comprising sophorolipid in combination with an antibiotic
AU2014364687B2 (en) * 2013-12-19 2017-09-14 Unilever Plc Composition
WO2015137357A1 (en) 2014-03-10 2015-09-17 サラヤ株式会社 Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition
WO2016013026A1 (en) * 2014-07-23 2016-01-28 Council Of Scientific & Industrial Research Curcumin-sophorolipid complex
US9364413B2 (en) * 2014-07-31 2016-06-14 Umo International Co., Ltd. Method for anti-aging treatment by surfactin in cosmetics via enhancing sirtuin
WO2016100826A1 (en) 2014-12-19 2016-06-23 Avelis Llc Mineral complex formulations for oral administration and methods for their use
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
KR20150037774A (en) 2015-02-13 2015-04-08 주식회사 감바이오팜 Preparation of clove having enhanced antioxidative effect
WO2016168197A1 (en) 2015-04-15 2016-10-20 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
EP3337454B1 (en) * 2015-08-20 2018-12-26 Unilever Plc. Improved lactam solubility
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US11590230B2 (en) 2015-12-07 2023-02-28 Elka Touitou Compositions of therapeutic substances, methods and uses thereof
US10155043B2 (en) 2015-12-29 2018-12-18 The United States Of America, As Represented By The Secretary Of Agriculture Compositions containing a bitter tastant and at least one sophorolipid, and methods of reducing bitter taste attributed to a bitter tastant in an edible composition
CN110769687A (en) 2017-04-20 2020-02-07 洛克斯Ip有限责任公司 Cost effective compositions and methods for enhancing aquaculture and ornamental fish feeding
CN116617384A (en) 2017-07-27 2023-08-22 轨迹Ip有限责任公司 Compositions for improving bioavailability of drugs, supplements and ingested substances
TWI814739B (en) 2017-09-08 2023-09-11 美商艾弗洛生物科技股份有限公司 Bacterial extracellular vesicles
US11478494B2 (en) 2017-10-13 2022-10-25 Locus Ip Company, Llc Methods and substances for prevention and treatment of neurodegenerative diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902512A (en) * 1987-01-22 1990-02-20 Director-General Of Agency Of Industrial Science And Technology And Shin-Etsu Chemical Co., Ltd. Rhamnolipid liposomes
US20050031549A1 (en) * 2003-06-09 2005-02-10 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
US20140255420A1 (en) * 2008-01-18 2014-09-11 The Brigham And Women's Hospital, Inc. Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders
CN103007287A (en) * 2012-09-29 2013-04-03 湖州紫金生物科技有限公司 Application of rhamnolipid as oral medicine absorbent accelerant
US20140187507A1 (en) * 2012-12-14 2014-07-03 Rutgers, The State University Of New Jersey Treatment of parkinsons disease with glycolipids

Also Published As

Publication number Publication date
EP3658124A4 (en) 2021-04-21
JP2024001005A (en) 2024-01-09
KR20200024940A (en) 2020-03-09
AU2018307361A1 (en) 2020-03-12
CN116617384A (en) 2023-08-22
IL272168A (en) 2020-03-31
CN111148511A (en) 2020-05-12
US20230201352A1 (en) 2023-06-29
CA3070711A1 (en) 2019-01-31
EP3658124A2 (en) 2020-06-03
US11590231B2 (en) 2023-02-28
ZA202000327B (en) 2021-10-27
CA3070711C (en) 2023-09-19
BR112020001759A2 (en) 2020-07-21
SG11202000670VA (en) 2020-02-27
TW201909919A (en) 2019-03-16
US20200164073A1 (en) 2020-05-28
JP2020528898A (en) 2020-10-01
WO2019023039A2 (en) 2019-01-31
MX2022014291A (en) 2022-12-07
US20230405127A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
WO2019023039A3 (en) Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
PH12020550051A1 (en) Glp-1 compositions and uses thereof
CL2018003105A1 (en) Amide substituted pyridinyltriazole derivatives and uses thereof.
WO2019219774A3 (en) Eutectic extract formation and purification
MX2016014509A (en) Formulation of fat-soluble vitamin.
WO2015189346A8 (en) Novel material mixture containing rubusoside or alpha-glycosylrubusoside, for enhancing sweet taste
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
WO2017008136A3 (en) Flourinated cbd compounds, compositions and uses thereof
WO2016005962A3 (en) Stable liquid formulations of cyclophosphamide and processes
EP3501524A4 (en) Use as immune enhancer or pharmaceutical composition for treatment of dementia, comprising phytosphingosine-1-phosphate or derivative thereof
PH12018501254A1 (en) Breakfast-replacement beverage and use of the composition
WO2016072692A3 (en) Composition for preventing or treating mucositis comprising necrox as effective ingredient
WO2017064635A3 (en) Saroglitazar magnesium, compositions containing it, process for its preparation
TR201906364T4 (en) Composition for the prevention or treatment of polycystic ovary syndrome and its related symptoms.
WO2019103875A3 (en) Methods of using and compositions containing dulaglutide
PH12019500024A1 (en) Pharmaceutical compositions
WO2019073127A3 (en) Composition containing cannabis oil
GB2530226A (en) Chewable tablet
MX2023003229A (en) Composition for enhanced absorption of supplements.
EA032385B9 (en) Pharmaceutical composition for treating gastrointestinal diseases
PH12020500022A1 (en) Salt of (ss)-adenosyl methionine with inositol hexaphosphate, and process for the preparation thereof
JP2016520588A5 (en)
WO2017188689A3 (en) Mixture of d-serine and caffeine and functional food composition containing same, for effect of preventing decline of learning ability or memory caused by stress, and effect of enhancing learning ability or memory
MX2019002647A (en) Tesofensine compositions.
PL413830A1 (en) Lactoferrin with manganese ions complex, method for obtaining it, application of the complex and pharmaceutical composition containing the complex of lactoferrin and manganese ions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18837671

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3070711

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020503843

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020001759

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20207004851

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2018837671

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018837671

Country of ref document: EP

Effective date: 20200227

ENP Entry into the national phase

Ref document number: 2018307361

Country of ref document: AU

Date of ref document: 20180719

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112020001759

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200127